Skip to main content
Fig. 2 | Biomarker Research

Fig. 2

From: Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

Fig. 2

Relationship between serum sCD26 titer variation and tumor volume variation by scatter plot analysis. The serum sCD26 titer variation from baseline (day 1pre, 100%) on a day 1post, b day 15pre, c day 15post, d day 29pre, e day 29post of YS110 administration, and tumor volume variation by RECIST response criteria on day 43 of a total of 25 cases was plotted. Data were separated into SD (gray circle) and PD (white circle) cohorts. The serum sCD26 titer variation from baseline on day 29pre of YS110 administration, and tumor volume variation by RECIST response criteria on day 43 of f 17 cases with Q2W administration, g 14 male cases with Q2W administration, h 18 MM cases, i 11 MM cases with Q2W administration, j 9 MM, male cases with Q2W administration, k 6 RCC cases with Q2W administration was plotted

Back to article page